Table 2.
Patient Demographics and Clinical Characteristics By Platelet:RBC ratio at 24 hours
| Characteristic | 0 N=384 |
0.1-0.9 N=100 |
1.0-2.0 N=172 |
2.1+ N=53 |
Total N=709 |
p-value |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age | 67.1 (55.4, 76.7) | 61.8 (51.0, 73.4) | 61.9 (50.9, 73.4) | 60.9 (47.1, 70.7) | 64.6 (52.8, 75.8) | 0.003 † |
| Male Sex | 226 (58.9%) | 71 (71.0%) | 90 (52.3%) | 27 (50.9%) | 414 (58.4%) | 0.02 ‡ |
| Charlson Score | 6.0 (3.5, 9.0) | 6 (3, 8) | 6 (3, 9) | 6 (4, 8) | 6 (4, 9) | 0.77 † |
| Massive Transfusion + | 21 (5.5%) | 63 (63.0%) | 54 (31.4%) | 11 (20.8%) | 149 (21.0%) | <0.001 ‡ |
| Patient Location | 0.009 ‡ | |||||
| ICU | 300 (78.1%) | 76 (76.0%) | 150 (87.2%) | 51 (96.2%) | 577 (81.4%) | |
| Emergency Room | 54 (14.1%) | 17 (17.0%) | 16 (9.3%) | 1 (1.9%) | 88 (12.4%) | |
| Floor | 30 (7.8%) | 7 (7.0%) | 6 (3.5%) | 1 (1.9%) | 44 (6.2%) | |
| Anatomical Site | 0.10 ‡ | |||||
| Gastrointestinal | 160 (41.7%) | 37 (37.0%) | 50 (29.1%) | 13 (24.5%) | 260 (36.7%) | |
| Intraabdominal | 71 (18.5%) | 19 (19.0%) | 37 (21.5%) | 10 (18.9%) | 137 (19.3%) | |
| Thoracic | 45 (11.7%) | 13 (13.0%) | 23 (13.4%) | 7 (13.2%) | 88 (12.4%) | |
| Hematologic | 19 (4.9%) | 11 (11.0%) | 7 (4.1%) | 3 (5.7%) | 40 (5.6%) | |
| Multifactorial | 15 (3.9%) | 3 (3.0%) | 11 (6.4%) | 2 (3.8%) | 31 (4.4%) | |
| Retroperitoneal | 15 (3.9%) | 4 (4.0%) | 9 (5.2%) | 2 (3.8%) | 30 (4.2%) | |
| Vascular | 12 (3.1%) | 2 (2.0%) | 9 (5.2%) | 7 (13.2%) | 30 (4.2%) | |
| Other | 25 (6.5%) | 4 (4.0%) | 12 (7.0%) | 5 (9.4%) | 46 (6.5%) | |
| Unknown | 22 (5.7%) | 7 (7.0%) | 14 (8.1%) | 4 (7.5%) | 47 (6.6%) | |
| Medical or Post-Surgical | 0.84 ‡ | |||||
| Medical | 270 (70.3%) | 73 (73.0%) | 120 (69.8%) | 35 (66.0%) | 498 (70.2%) | |
| Post-Surgical | 114 (29.7%) | 27 (27.0%) | 52 (30.2%) | 18 (34.0%) | 211 (29.8%) | |
| Plasma:RBC Ratio | <0.001 ‡ | |||||
| 0 | 202 (52.6%) | 6 (6.0%) | 31 (18.0%) | 13 (24.5%) | 252 (35.5%) | |
| 0.1-0.4 | 81 (21.1%) | 37 (37.0%) | 46 (26.7%) | 8 (15.1%) | 172 (24.3%) | |
| 0.5-0.9 | 68 (17.7%) | 45 (45.0%) | 69 (40.1%) | 22 (41.5%) | 204 (28.8%) | |
| 1.0+ | 33 (8.6%) | 12 (12.0%) | 26 (15.1%) | 10 (18.9%) | 81 (11.4%) | |
| RBC Units | 4 (3, 6) | 10 (8, 14) | 6 (4, 9) | 5 (4, 6) | 5 (4, 7) | <0.001 † |
| Laboratory values before CAT+ | ||||||
| Hemoglobin, g/dL | 7.3 (6.0, 9.1) | 7.7 (6.3, 9.1) | 7.3 (6.1, 9.0) | 6.8 (6.0, 8.0) | 7.3 (6.0, 9.0) | 0.14 † |
| Platelet Count, x109/L | 181 (128, 269) | 159 (105, 254) | 104 (60, 146) | 43 (29, 69) | 148 (89, 225) | <0.001 † |
| INR | 1.3 (1.1, 1.7) | 1.3 (1.2, 1.8) | 1.4 (1.2, 1.8) | 1.5 (1.3, 1.9) | 1.3 (1.1, 1.8) | 0.02 † |
| Medications before CAT+ | ||||||
| Heparin | 37 (9.6%) | 10 (10.0%) | 18 (10.5%) | 4 (7.5%) | 69 (9.7%) | 0.94 § |
| Direct thrombin inhibitor | 5 (1.3%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 5 (0.7%) | 0.23 ‡ |
| Warfarin | 83 (21.6%) | 10 (10.0%) | 19 (11.0%) | 7 (13.2%) | 119 (16.8%) | 0.003 ‡ |
| Aspirin | 188 (49.0%) | 36 (36.0%) | 67 (39.0%) | 17 (32.1%) | 308 (43.4%) | 0.01 ‡ |
| Clopidogrel | 36 (9.4%) | 10 (10.0%) | 11 (6.4%) | 5 (9.4%) | 62 (8.7%) | 0.66 ‡ |
| LMW Heparin | 36 (9.4%) | 4 (4.0%) | 10 (5.8%) | 2 (3.8%) | 52 (7.3%) | 0.14 § |
| Factor Xa | 6 (1.6%) | 0 (0.0%) | 2 (1.2%) | 1 (1.9%) | 9 (1.3%) | 0.63 § |
| Hemostatic medications | ||||||
| Vitamin K | 40 (10.4%) | 13 (13.0%) | 22 (12.8%) | 10 (18.9%) | 85 (12.0%) | 0.32 ‡ |
| Antifibrinolytic agents | 11 (2.9%) | 3 (3.0%) | 9 (5.2%) | 4 (7.5%) | 27 (3.8%) | 0.25 § |
| PCCs | 3 (0.8%) | 1 (1.0%) | 7 (4.1%) | 0 (0.0%) | 11 (1.6%) | 0.02 § |
Numbers indicate N (%) unless otherwise noted.
†
Kruskal-Wallis
‡
Chi-square
§
Fisher exact
Massive transfusion + defined as administration of ≥10 units of RBCs within 24 hours.
Abbreviations: RBC, red blood cells; INR, international normalized ratio; LMW, low molecular weight heparin; CAT, critical administration threshold; PCC, prothrombin complex concentrate